The Wilms' tumor 1 gene (WT1) encodes a transcription factor of the zinc-®nger family and is homozygously mutated or deleted in a subset of Wilms' tumors. Through alternative mRNA splicing, the gene is expressed as four main polypeptides that dier by a stretch of 17 amino acids just N-terminal of the four zinc-®ngers and three amino acids between zinc ®ngers 3 and 4. We have previously shown that expression of the WT1(7/7) isoform, lacking both inserts, increases the tumor growth rate of the adenovirus-transformed baby rat kidney (AdBRK) cell line 7C3H2, whereas expression of the WT1(7/+) isoform, lacking the 17aa insert, strongly suppresses the tumorigenic phenotype. In the present study we show that expression of these splice variants does not aect the tumorigenic potential of the similar AdBRK cell line, 7C1T1. In contrast to the 7C3H2 cell line, this AdBRK cell line expresses high endogenous levels of EGR-1 (early growth response-1) protein, a transcription factor structurally related to WT1. Ectopic expression of EGR-1 in the 7C3H2 AdBRK cells signi®cantly increases their in vivo growth rate and nulli®es the tumor suppressor activity of the WT1(7/+) protein. Furthermore, we ®nd that EGR-1 levels are elevated in some Wilms' tumors. These data are the ®rst to show that EGR-1 overexpression causes enhanced tumor growth and that WT1 and EGR-1 exert antagonizing eects on growth regulation in baby rat kidney cells, which might re¯ect the situation in some Wilms' tumors. Oncogene (2000) 19, 791 ± 800.
Introduction
Wilms' tumor is a pediatric malignancy of the kidney that was ®rst described by Max Wilms in 1899. Although several chromosomal regions may be involved in the development of Wilms' tumor (Bonetta et al., 1990; Gessler et al., 1992; Slater and Mannens, 1992) , only one gene has been cloned: the WT1 gene (Call et al., 1990) . About 10% of all Wilms' tumors have homozygous mutations in the WT1 gene and, consequently, WT1 was classi®ed as a tumor suppressor gene.
As a result of alternative mRNA splicing, the gene is expressed as four main isoforms, which dier by the presence or absence of two stretches of amino acids: one of 17 residues just N-terminal of the four zinc ®ngers (+17aa) and one of three residues (K-T-S) between zinc ®ngers 3 and 4 (+KTS) (Haber et al., 1991) . Presence or absence of the KTS insert determines the DNA-binding speci®city of WT1 (Bickmore et al., 1992; Nakagama et al., 1995; Rauscher et al., 1990) , while the 17 amino acid insert may function as a transcription regulatory domain . The dierent WT1 isoforms may dierentially regulate the same target genes. In support of this, it has been shown that the WT1(+KTS) and the WT1(7KTS) can bind overlapping DNA sequences in the promoters of the IGF-II gene Duarte et al., 1998; Wang et al., 1995) , the gene for the PDGF-A chain (Wang et al., 1995) , the WT1 gene and the PAX-2 gene (Ryan et al., 1995) . It has recently been shown that, within one cell type, WT1 (7KTS) activates whereas WT1(+KTS) represses transcription from the murine IGF-II P3 promoter (Duarte et al., 1998) . However, the transcriptional eects of WT1 are not well understood, since a single WT1 isoform may, depending on promoter architecture, expression vector and cell line used, activate or repress transcription from reporter constructs (reviewed in Menke et al., 1998) .
The eects of dierent WT1 isoforms on tumorigenicity have been tested in a number of cell lines. Expression of the WT1(7/+) isoform suppresses the tumorigenic potential of G401 cells (McMaster et al., 1995) and 7C3H2 cells, while expression of this splice variant in HT 1080 cells (McMaster et al., 1995) does not have any eect. Expression of the WT1(7/7) isoform suppresses the tumorigenicity of ras-transformed NIH3T3 cells (Luo et al., 1995) and increases the tumorigenicity of 7C3H2 cells (Menke et al., 1996) . These data indicate that the eects of the various splice variants on tumorigenicity are cell line dependent. Another transcription factor which binds to partially the same DNA sequences as WT1 is the EGR-1 protein, an immediate early gene product. The EGR-1 transcript is rapidly induced after stimulation of quiescent cells with a variety of stimuli (Lau and Nathans, 1987; Lim et al., 1987; Milbrandt, 1987) , suggesting that EGR-1 is involved in controlling cell growth. In line with EGR-1 being expressed in growing cells, high EGR-1 levels have been found in prostate cancer tissue compared to normal prostate tissue (Eid et al., 1998; Thigpen et al., 1996) . However, in lung carcinomas EGR-1 levels are downregulated compared to adjacent normal lung tissue (Levin et al., 1995) . Moreover, the tumorigenicity of a subclone of HT 1080 ®brosarcoma cells, which expresses little or no endogenous EGR-1, is markedly reduced upon overexpression of EGR-1 . Thus, the eect of EGR-1 on cell growth may also be cell type speci®c.
Like WT1, the EGR-1 protein contains zinc-®ngers of the Cys2 ± His2 subclass in its carboxy-terminal part. Zinc ®ngers 2, 3 and 4 of WT1 exhibit 61 per cent amino acid homology with three zinc ®ngers of EGR-1 (Rauscher, 1993) . It is, therefore, conceivable that EGR-1 regulates partly the same target genes as WT1. Transient transfection assays show that WT1 may suppress the promoter activity of several growthrelated genes which EGR-1 can activate, e.g. transforming growth factor b (TGFb) (Dey et al., 1994) , insulin-like growth factor II (Lee and Kim, 1996) and the G protein ai-2 subunit (Kinane et al., 1994 (Kinane et al., , 1995 , although the eects may again be cellline dependent. Reciprocal expression of WT1 and EGR-1 has been observed during dierentiation of LLC-PK1 kidney cells (Kinane et al., 1994 (Kinane et al., , 1995 . Maximum EGR-1 expression coincided with proliferation and maximum activity of the Gai-2 promoter, which contains an EGR-1 consensus sequence, whereas maximum WT1 expression coincided with suppression of this promoter activity and dierentiation. Thus, WT1 and EGR-1 may exert distinct eects on cell growth and tumorigenicity, possibly by modulating the transcription of an overlapping set of target genes.
We have previously shown that expression of the WT1(7/+) protein, lacking the 17aa insert, strongly suppresses the tumorigenic phenotype of 7C3H2 AdBRK cells in nude mice (Menke et al., 1995 (Menke et al., , 1996 , suggesting that WT1(7/+) functions as a tumor suppressor in these cells. In support of such function, the expression of the WT1(7/+) protein was lost in the tumors that arose after a prolonged latency period. In contrast, expression of the WT1(7/7) protein in 7C3H2 cells increased the tumor growth rate (Menke et al., 1996) and in agreement with a tumor-growth-promoting-function, the WT1(7/7) protein was still expressed in the tumors.
In this study, we demonstrate that expression of neither WT(7/7) nor WT1(7/+) has any eect on the tumorigenicity of the similar 7C1T1 AdBRK cell line that contains about tenfold more EGR-1 protein than 7C3H2 cells, suggesting that EGR-1 may account for the abrogation of WT1 eects. Indeed, ectopic expression of EGR-1 in the 7C3H2 cell line increases the tumor growth considerably and nulli®es the tumor suppressive eect of the WT(7/+) isoform. In addition, we ®nd that some Wilms' tumors express high EGR-1 levels compared to normal kidney tissue, suggesting that EGR-1 may contribute to the development of some Wilms' tumors. These data are the ®rst to show that EGR-1 overexpression causes enhanced tumor growth and that WT1 and EGR-1 exert antagonizing eects on tumor growth regulation within one cell system, which might re¯ect the situation in some Wilms' tumors.
Results

Establishment of monoclonal WT1-transfectants
To test the eect of the WT1(7/7) and (7/+) splice variants on the tumorigenicity of 7C1T1 AdBRK cells, these cells were transfected with the two human WT1 cDNA constructs WT1(7/7) and WT1(7/+), which were shown to alter the tumorigenicity of 7C3H2 cells (Menke et al., 1996) , or the expression vector without a cDNA insert and monoclonal cell lines were established. By Western analysis, WT1 expression was undetectable in both the parental 7C1T1 cells and the 7C1T1-derived cell line E7, which contains the empty expression construct (Figure 2a ). The two 7C1T1-derived cell lines A8 and A11 express WT1(7/7), while the lines C2 and C7 synthesize WT1(7/+) proteins. All AdBRK cells used in this study express comparable amounts of adenoviral proteins as assessed by Western blot analysis (data not shown). For a schematic overview of all cell lines used in this study see Figure 1 .
In vivo growth properties
To determine the eects of expression of the WT1 splice variants on the oncogenic phenotype of the 7C1T1 AdBRK cells, two transfectants of each WT1 isoform were subcutaneously injected into two athymic mice (two sites each), and the diameters of the developing tumors were measured at several time points after injection. Although both the latency period and the tumor take of the 7C1T1 cell lines were similar to what we had observed for the 7C3H2 cell lines (Menke et al., 1996) , 7C1T1 cells induced faster growing tumors compared to 7C2H2 cells and expression of the WT1(7/7) or the WT1(7/+) isoform did not alter the tumorigenic potential of 7C1T1 cells (Figure 2b,c) . Similar to the results obtained with the 7C3H2 transfectants (Menke et al., 1996) , WT1(7/7) protein could still be detected in the tumors induced by the A8 and A11 transfectants (Figure 2b : A8T, A11T). However, in contrast to the tumors induced by the 7C3H2 WT1(7/+) transfectants (Menke et al., 1996) , the tumors C2T and C7T induced by the 7C1T1 WT1(7/+) transfectants, retained expression of WT1(7/+) ( Figure 2c ). These ®ndings indicate that the WT1(7/+) isoform does not function as a tumor suppressor in the 7C1T1 cell line and that factors present in these cells may overrule the eects WT1 has on the tumorigenicity of 7C3H2 cells.
EGR-1 protein levels in 7C1T1 cells are higher than in 7C3H2 cells
Since WT1 can function as a transcription regulator, we speculated that proteins which can bind to the same DNA sequences as WT1 may abrogate its eect on the tumorigenicity of 7C1T1 cells. To investigate the WT1-like DNA-binding activities present in 7C1T1 and 7C3H2 cells, we performed electrophoretic mobility shift assays (Figure 3a) . Nuclear extracts of the 7C1T1 EGR-1 enhances tumor growth and modulates WT1 function V Scharnhorst et al and 7C3H2 transfectants were incubated with the WTE DNA sequence (Nakagama et al., 1995) . As described previously, only the WT1(7KTS) isoform bound to the WTE sequence (Nakagama et al., 1995) : no basal shift could be detected in the 7C3H2/C7 cell line. The addition of an anti-WT1 antibody (lanes WT1 in Figure 3b ) induced a supershift in the WT1(7/7) expressing transfectants A8 and A9, but not in the WT1(7/+) expressing transfectants C2 and C7. Although no WT1 could be detected in nuclear extracts of 7C3H2/50.1 and 7C1T1/E7 cells on a Western blot (Figure 3b ), the electrophoretic mobility shift assay with nuclear extracts of the 7C1T1/E7 transfectant shows a speci®c basal shift ( Figure 3a , lanes shift) at approximately the same height as the WT1(7/7)-containing complex present in nuclear lysates of AdBRK transfectants A8 and A9.
To investigate the nature of this basal shift present in 7C1T1 cells, we added antibodies to the reaction mixture, which were raised against proteins that could bind to similar DNA sequence as WT1. While addition of an anti-SP1 antibody had no eect on the DNAbinding complex (data not shown), addition of an anti-EGR-1 antibody resulted in a supershift of almost the entire basal complex (Figure 4a , lanes EGR-1), indicating that EGR-1 is the only WTE-binding protein in these cells.
Initially, the EGR-1-WTE complex appeared to be present in nuclear extracts of the 7C1T1 AdBRK cell lines only. However, an overexposure as shown in Figure 4a revealed that this complex is also present in extracts of the 7C3H2 AdBRK cells, albeit at much lower levels. To determine whether the relatively high amount of EGR-1 present in the mobility shift of (E7) and 7C1T1 cells stably expressing WT1(7/7) or WT1(7/+). Tumor growth curves of (b), the 7C1T1/WT1(7/ 7) transfectants, (c), the 7C1T1/WT1(7/+) transfectants and the control transfectant 7C1T1/E7. The mean of tumor growth curves of the 7C3H2/50.1/H1, -H2 and -He cell lines shown in Figure 5c is included as a comparison (7C3H2/50.1/H). Expression of WT1(7/7) or WT1(7/+) has no eect on the tumorigenicity of 7C1T1 cells. Western analysis shows that WT1 expression is retained in all tumors (A8T, A11T; C2T, C7T) EGR-1 enhances tumor growth and modulates WT1 function V Scharnhorst et al 7C1T1 cells is due to higher steady state levels of EGR-1 protein, we performed Western analysis. As can be seen in Figure 4b , the steady-state level of EGR-1 protein in nuclear extracts of 7C1T1 AdBRK cells is much higher than in 7C3H2 AdBRK cells. EGR-1 is undetectable in whole cell lysates of exponentially growing 7C3H2/50.1 cells (Figure 4b , lane exp.), but is detected after stimulation of starved cells with epidermal growth factor ( Figure 4b , lanes E,G,F).
Thus, proliferating 7C1T1 cells contain about tenfold more EGR-1 protein than do exponentially growing 7C3H2 cells.
Establishment of monoclonal 7C3H2-transfectants expressing the EGR-1 protein EGR-1 upregulation has been associated with proliferation, transformation and tumorigenesis (Gashler and Sukhatme, 1995) and increased EGR-1 levels were found in e.g. prostate carcinoma (Eid et al., 1998; Thigpen et al., 1996) . We hypothesized that in the 7C1T1 cell line, EGR-1 is responsible for the increase in tumor growth rate compared to 7C3H2 cells and abrogates the tumor suppressor activity of the WT1(7/+) splice variant. To prove a causal role for EGR-1 in tumor outgrowth, we tested whether expression of exogenous EGR-1 in 7C3H2 cells would increase the tumor growth rate of these cells and whether EGR-1 could counteract the tumor suppressive eect of the WT1(7/+) splice form. To that end, we stably transfected an EGR-1 expression plasmid into the 7C3H2/50.1 transfectant containing the empty expression plasmid only and the 7C3H2/WT1(7/+) transfectant C7. Figure 5a shows two monoclonal 7C3H2/50.1-derived cell lines, E3 and E7, synthesizing high amounts of EGR-1 protein and three 7C3H2/50.1-derived monoclonals containing the empty expression plasmid and the hygromycin selection marker only (7C3H2/50.1/ H1-H3). Expression of EGR-1 in 7C3H2/50.1/E3 and -E7 is several fold higher than the expression level of endogenous EGR-1 in 7C1T1 cells. As expected, no WT1 expression could be found in these cells. In Figure  5b , 7C3H2/C7-derived transfectants are shown that express either WT1(7/+) alone (7C3H2/C7/H1, -H3 and -H4) or WT1(7/+) and EGR-1 (7C3H2/C7/E1, -E9, -E18). The last lane contains lysate of 7C1T1/C2 cells, which express endogenous EGR-1 and exogenous WT1(7/+) proteins. All 7C3H2 transfectants express equal amounts of adenoviral proteins and have similar growth rates in tissue culture (data not shown). The 7C3H2/50.1-derived cell lines were subcutaneously injected into athymic mice and the tumor diameters were measured at several time points after injection ( Figure 5c ). Latency period and tumor-take of the control cell lines 7C3H2/50.1/H1, -H2 and -H3 are similar to the parental 7C3H2/50.1 line (Menke et al., 1996) , demonstrating that introduction of the vector alone has no eect on tumor growth. However, constitutive expression of EGR-1 in 7C3H2/50.1/E3 and -E7 cells results in a marked increase of the tumor growth rate (Figure 5c ). Interestingly, the tumor growth of AdBRK cells in nude mice correlates with the expression level of EGR-1. 7C3H2 cells containing little EGR-1 grow slower than 7C1T1 cells containing high endogenous EGR-1 (Figure 2b,c) . 7C3H2 cells ectopically expressing EGR-1 to levels higher than in 7C1T1 cells grow faster than 7C1T1 cells (Figure 5c ). Western analysis demonstrated that EGR-1 is present in the EGR-1 expressing cells and is retained in the recovered tumor material (Figure 5c ).
EGR-1 expression counteracts the tumor suppressor activity of the WT1(7/+) isoform in 7C3H2 cells 7C3H2 cells containing the WT1(7/+) form and the hygromycin-resistance vector form tumors with marginally reduced latency period only (Figure 5d ) when compared to the 7C3H2/50.1 cells expressing the hygromycin resistance gene (Figure 5c ). However, immuno¯uorescence analysis of the 7C3H2/C7/H1, -H3 and -H4 transfectants revealed that, in contrast to the transfectants used in previous experiments (Menke et al., 1996) , WT1(7/+) was not expressed in all cells of these three cell lines. The loss of the prolonged latency period we have observed before (Menke et al., 1996) may thus be caused by rapid outgrowth of those cells that lacked WT1(7/+) expression at the time of injection. Importantly, analysis of the tumor material by Western blot showed loss of WT1(7/+) expression (7C3H2/C7/H1T, -H3T, -H4T in Figure 5d ), suggesting a strong selection against WT1 expression and/or WT1-expressing cells during tumor outgrowth, as we have reported before (Menke et al., 1996) . Ectopic expression of EGR-1 in WT1(7/+) expressing 7C3H2 cells signi®cantly increases the tumor growth rate (Figure 5d ). The tumors grow faster than those induced by WT1(7/+)-expressing 7C3H2 cells (Figure 5d ), but slower than those caused by EGR-1-expressing 7C3H2 cells ( Figure  5c ). Importantly, these tumors still express WT1(7/+) protein at unaltered levels (7C3H2/C7/E1T, -E9T, E18T in Figure 5d ). These data demonstrate that EGR-1 expression can overrule the tumor suppressor activity of WT1(7/+) in the AdBRK system to some extent and that expression of EGR-1 is sucient to abrogate the need for loss of WT1(7/+) during tumor outgrowth. Thus, EGR-1 and WT1(7/+) may exert opposite eects on tumor growth regulation, and the unaltered expression of WT1 in the 7C1T1 AdBRK-induced tumors ( Figure  2c ) may be due to the high endogenous levels of EGR-1 in these cells (Figures 4b and 5a,b) .
Wilms' tumors contain elevated levels of EGR-1 mRNA
In humans, approximately 90% of all Wilms' tumors are sporadic and only 5% of these show intragenic WT1 mutations (Little and Wells, 1997) . Thus, WT1 is present in most Wilms' tumors. We hypothesized that EGR-1 expression may overrule the tumor suppressing activity of WT1 in some of these cases. Therefore, we determined the EGR-1 mRNA levels in samples of normal kidney and Wilms' tumors by Northern analysis. Out of 16 tumors tested three contained increased levels of EGR-1 mRNA compared to normal kidney ( Figure 6a , upper panel; tumors 29, 19 and 77), while the other 13 have EGR-1 levels similar to normal kidney (data not shown). In order to determine WT1 protein levels in the tumor samples with elevated EGR-1 levels, we extracted protein from these specimens and the corresponding control tissues. As expected, all normal kidney samples contain WT1 protein ( Figure  6b ). Tumors 29 and 19 have lost WT1 protein expression while tumor 77 retains WT1 proteins.
Discussion
In this study we present data demonstrating that the eects of the Wilms' tumor 1 proteins on tumor growth are cell line dependent, and that the EGR-1 expression level might be an important determinant. Expression of WT1(7/7) or WT1(7/+) has no eect on the tumorigenicity of the 7C1T1 AdBRK cell line, Figure 4 High levels of EGR-1 protein bind to the WTE DNA motif in 7C1T1 cells. (a) 20, 10 and 5 mg of 7C3H2/50.1 and 7C1T1/E7 AdBRK cell nuclear extracts were incubated with a labeled WTE DNA motif, in the presence of a 100-fold excess of unlabeled WTE DNA motif (lanes comp.), a 100-fold excess of an aspeci®c competitor (lanes asp.c.), an anti-WT1 antibody (lanes WT1), or an anti-EGR-1 antibody (lanes EGR-1). (b) A Western blot, containing 20 mg of nuclear extract or 50 mg of whole cell extract per lane, was incubated with an anti-EGR-1 antibody. Nuclear extract of AdBRK cells cultured in 8% serum (lanes nucl.), total cell lysates of AdBRK cells cultured in 8% serum (lanes exp.), serum-starved for 24 h (lanes starved) or stimulated for 2 h with 100 ng/ml epidermal growth factor after starvation (lanes EGF) were tested EGR-1 enhances tumor growth and modulates WT1 function V Scharnhorst et al while we have previously shown that the WT1(7/7) isoform increases and the WT1(7/+) isoform suppresses the tumorigenic potential of the similar 7C3H2 AdBRK cell line (Menke et al., 1995 (Menke et al., , 1996 . We now show that the 7C1T1 and the 7C3H2 cell lines dier with respect to the amount of EGR-1 protein expressed. Ectopic expression of EGR-1 in 7C3H2 cells increases the growth rate of the tumors induced by these cells and co-expression of EGR-1 and WT1(7/+) abrogates the tumor suppressive function of the WT1(7/+) form. To our knowledge, this is the ®rst study to show that overexpression of EGR-1 enhances tumor growth and to report opposite growth regulatory eects of WT1 and EGR-1 in one cell system.
Tumorigenicity tests with dierent WT1 isoforms have now been performed in a number of cell lines. Expression of the WT1(7/+) isoform suppresses the tumorigenic potential of G401 (Mcmaster et al., 1995) and 7C3H2 cells (Menke et al., 1995 (Menke et al., , 1996 , while , 1995) or 7C1T1 cells (this study) does not have any eect. Expression of the WT1(7/7) isoform suppresses the tumorigenicity of ras-transformed NIH3T3 cells (Luo et al., 1995) , increases the tumorigenicity of 7C3H2 cells (Menke et al., 1996) and has no eect on the tumor growth of the 7C1T1 cell line (this study). Thus, the eects of the various splice variants on tumorigenicity are cell line dependent. The question remains which factors determine the eects of the WT1 proteins on cell growth. One ubiquitously expressed protein that has been described to aect WT1 function is p53. Co-transfection of p53 and WT1 into p53-negative Saos-2 cells converts WT1 from a transcriptional activator of the EGR-1 promoter to a repressor, whereas mutant p53 does not (Maheswaran et al., 1993) . The 7C3H2 cell line expresses p53 with a C to T mutation at codon 156 (van den Heuvel et al., 1993) , while the 7C1T1 cells express wild-type p53 as determined with conformation-speci®c antibodies (data not shown). Thus, the cell type-dependent eects could be explained by the status of p53. In adenovirus-transformed cells, however, p53 is functionally inactivated by the adenoviral E1 proteins (Steegenga et al., 1995; Yew and Berk, 1992) . In addition, the WT1(7/7) isoform suppresses the tumorigenicity of ras-transformed NIH3T3 cells (Luo et al,. 1995) , but has no eect on the tumorigenic potential of the 7C1T1 cells (this study), while both cell lines express wild-type p53. Maheswaran et al. (1998) recently found that the adenovirus type 5 E1B 55K protein forms trimeric complexes with p53 and WT1 in adenovirus type 5-transformed BRK cells, which are sequestered in cytoplasmic bodies. In the AdBRK cells used for this study, WT1 exclusively localizes to the nucleus (data not shown), probably due to the fact that these cells were transformed with the E1A region of adenovirus type 5 and the E1B region of adenovirus type 12. The large E1B protein of adenovirus type 12 appears not to bind to p53 (Zantema et al., 1985) . These results all indicate that the eects of WT1 are modulated by other factors in addition to a possible eect of p53.
We show here that EGR-1 may be one of these factors. Physical association between WT1 and EGR-1 as a means to modulate WT1 function does not seem likely, since we were unable to detect direct binding of WT1 to EGR-1 in spite of extensive analysis (data not shown). Although the mechanism by which EGR-1 counteracts the eect of WT1 is unknown, this study clearly demonstrates functional interaction between the two proteins: one common ®nding of all reports in which a WT1 isoform acts as tumor suppressor is, that WT1 expression is lost during tumor outgrowth (Luo et al., 1995; McMaster et al., 1995; Menke et al., 1996) . Strikingly, we ®nd that WT1(7/+) expression is not lost in tumors which co-express high levels of EGR-1, either endogenous or exogenous, indicating that EGR-1 counteracts WT1(7/+) in such a way that continuous WT1(7/+) expression is compatible with tumor outgrowth.
Since WT1 and EGR-1 are highly homologous in their zinc-®nger domains, dierentially regulate transcription from reporter constructs (Dey et al., 1994; Kinane et al., 1994 Kinane et al., , 1995 Lee and Kim, 1996) , and have opposite eects on cell growth (Kinane et al., 1994 (Kinane et al., , 1995 , it is conceivable that the opposing eects of WT1(7/+) and EGR-1 on tumor growth are due to opposite regulation of common target genes. We have, however, no proof for that and can not exclude the possibility that the opposite eects on tumorigenicity are attributable to transcriptional regulation of distinct target genes.
In contrast to its oncogenic eect in AdBRK cells, EGR-1 has been reported to suppress tumorigenicity. The tumorigenicity of a subclone of HT 1080 ®brosarcoma cells, which expresses little endogenous EGR-1, is markedly reduced by overexpression of EGR-1. Overexpression of the DNA-binding domain of EGR-1 had a similar eect . Later, it has been shown that the secretion of TGFb by this subclone of HT1080 cells is proportional to the Figure 6 Wilms' tumors express elevated levels of EGR-1 mRNA. (a) Twenty mg of RNA of each sample was loaded and the Northern blots probed with a human EGR-1 or a GAPDH probe to con®rm equal loading of RNA. N29 and T29, normal kidney and Wilms' tumor material from one patient; N1 and N2, two normal kidney samples; T19 and T77, samples from two Wilms' tumor patients; +, RNA of U20S cells serum-starved for 24 h prior to stimulatioan with 100 ng/ml epidermal growth factor for 1 h. (b) Western analysis of WT1 levels in Wilms' tumors and normal kidney material. Proteins were detected on blots containing 100 mg of protein per lane with a 3 h exposure of the X-ray ®lm to the blot to visualize the relatively low levels of WT1 EGR-1 enhances tumor growth and modulates WT1 function V Scharnhorst et al expression level of exogenous EGR-1 in these cells and secretion of TGFb by these cells is inversely correlated with their proliferation in tissue culture (Liu et al., 1996) . Thus, EGR-1 may exert its suppressive eect on tumorigenicity via transcriptional regulation of the TGFb gene. Since growth regulation by TGFb is completely abrogated in cells expressing the adenoviral E1A proteins (de Groot et al., 1995) , EGR-1 may not be able to exert its growth inhibitory eect. In analogy, prostate carcinomas express elevated levels of TGFb (Royuela et al., 1998) , but prostate carcinoma cells are insensitive to growth inhibition by TGFb (Cipriano and Chen, 1998) . Thus, in AdBRK cells as well as in prostate carcinoma cells, EGR-1 may activate a growth stimulatory pathway which would otherwise be masked by the growth suppressive eect of TGFb.
EGR-1 expression is found in almost all proliferating cells, including the metanephric blastema, where it is ordinarily down-regulated during renal development (Rackley et al., 1995) . Wilms' tumors are thought to arise from mesenchymal blastema cells that fail to dierentiate properly but continue to proliferate (Machin and McCaughey, 1984) , raising the interesting possibility that deregulation and subsequent overexpression of EGR-1 may, in some cases, play a causal role in the development of Wilms' tumor. Indeed, we ®nd that three out of 16 Wilms' tumors tested express elevated levels of EGR-1, which may contribute to continuous growth, instead of dierentiation, of the tumor cells as has been found in vitro dierentiation of kidney cells (Kinane et al., 1994 (Kinane et al., , 1995 . One of these three tumors retains expression of WT1, whereas the other two do not contain WT1 protein. Since WT1 can repress the EGR-1 promoter , loss of WT1-mediated transcriptional repression in the other two tumors may lead to continuous synthesis of EGR-1 protein during renal dierentiation and subsequently to tumor formation. Strikingly, the 13 Wilms' tumors with unaltered EGR-1 levels all express full-length WT1 proteins (data not shown). To address the question whether a correlation between overexpression of EGR-1 and loss of WT1 exists, a larger panel of Wilms' tumors needs to be analysed.
Elevated levels of EGR-1 may contribute to continuous proliferation of Wilms' tumors. Alternatively, the increase of EGR-1 mRNA could be a consequence of tumor formation rather than a cause. However, our data show that overexpression of EGR-1 is sucient to increase proliferation of AdBRK cells in nude mice. Further research into the role of EGR-1 in the development of Wilms' tumor is necessary to discriminate between overexpression of EGR-1 contributing to or being a mere consequence of Wilms' tumor formation.
Materials and methods
Cell lines and tissue culture
All cells were cultured at 378C, 5% CO 2 , in modi®ed Eagle's medium supplemented with 8% newborn-calf serum (GIB-CO ± BRL) and antibiotics, except U20S cells which were grown in Dulbecco's modi®ed Eagle's medium supplemented with 8% fetal calf serum and antibiotics. The 7C1T1 ± 7C1 cell line are baby rat kidney cells, transformed by a recombinant plasmid containing region E1A from adenovirus type 5 and region E1B from adenovirus type 12 (Bernards et al., 1982) . The 7C1T1 cell line is derived from the Ad512 ± 7C1 cell line, which had been injected into nude mice. Subsequently, the tumor was excised and the tumor cells were taken into culture. The 7C1T1 AdBRK cell line was stably transfected with two dierent human WT1 cDNA constructs coding for the WT1(7/7) and WT1(7/+) isoforms (Morris et al., 1991) . After transfection, the cells were cultured in selective medium (400 mg/ml neomycin) and monoclonal cell lines were established. The 7C3H2 AdBRK cell line is an HPRT-negative derivative (Ad512 ± 7C3H2) derived from the Ad512 ± 7C3 cell line. The Ad512 ± 7C3 cells are baby rat kidney cells, transformed by a recombinant plasmid containing region E1A from adenovirus type 5 and region E1B from adenovirus type 12 (Bernards et al., 1982) . Transfectant 7C3H2/50.1 is a 7C3H2 AdBRK cell line containing the empty CB6+ vector. Transfectant A9 expresses the WT1(7/7) protein isoform and transfectant C7 the WT1(7/+) protein. Transfectants 7C3H2/50.1/H1, -H2, -H3 and 7C3H2/C7/H1, -H3, -H4 are derived from the 7C3H2/50.1 cell line and the 7C3H2/C7 cell line, respectively, and contain the CB6+ and a hygromycin-resistance vector (pECV5). Transfectants 7C3H2/50.1/E3, -E7 and 7C3H2/C7/ E1, -E9, -E18 are derived from the 7C3H2/50.1 cell line and the 7C3H2/C7 cell line, respectively, and contain the CB6+ vector with a murine EGR-1 cDNA insert and the hygromycin-resistance plasmid, pECV5. Stably transfected cells were selected in medium containing 100 mg/ml hygromycin (GIBCO ± BRL). For a schematic overview of the cells used in this study see Figure 1 .
Tumorigenicity asay
Six-week-old female athymic mice (NUD-NU/NU BR Harlan) were injected subcutaneously with 1*10 6 cells in 150 ml PBS per site, two sites per animal, two (for 7C1T1-derived cells) or three (for 7C3H2-derived cells) animals per cell line. The tumor diameters were measured at several time points after injection.
Antibodies
Antibodies against the following antigens were used in this study: WT1 (C19), EGR-1 (588), Sp1 (PEP2), all from Santa Cruz Biotechnology.
Western analysis
Cells were grown on 9-cm dishes to 70% con¯uence, washed twice with ice-cold PBS and lysed in 1/2 RIPA buer (20 mM TEA pH 7.8, 0.14 M NaCl, 0.05% DOC, 0.05% SDS, 0.05% Triton X-100) or IPB 0.7 buer (20 mM TEA pH 7.8, 0.7 M NaCl, 0.5% NP-40, 0.2% DOC) supplemented with inhibitors (1 mM PMSF, 0.1 mg ml 71 NaF, 8-glycero-phosphate, Na 3 VO 4 , Trypsin inhibitor and 1 mg ml 71 Na 4 P 2 O 7 ). Chemotherapeutically pretreated Wilms' tumor material and, when distinguishable from tumor tissue, non malignant kidney tissue were collected during nephrectomy. Frozen tumor material was fragmented in a micro dismembrator (B Braun AG, Germany) prior to lysis in IPB 0.7. The protein concentration was determined with the Bradford assay (Biorad). Proteins, 50 mg of each sample, were separated on a 10% SDS-Polyacrylamide gel and subsequently transferred onto an Immobilon-P transfer membrane (Millipore) in icecold blotting buer containing 20% methanol, 20 mM Tris, and 150 mM glycine at 300 mA for 3 h. The blots were blocked for 30 min in TBST (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.2% Tween-20) containing 5% non-fat dry milk (Nutricia), subsequently incubated for 1 h with the ®rst antibody and 30 min with the second antibody coupled to horse-radish peroxidase (Jackson ImmunoResearch Laboratories), diluted in the blocking buer. Protein bands were visualized by enhanced chemiluminescence.
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